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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of diabetes self-management (DSM) interventions for people with type 2 diabetes with severe mental illness (SMI).
B A C K G R O U N D
Description of the condition
Diabetes is a common and serious global health problem, cur-
rently affecting an estimated 8.3% of adults - 382 million peo-
ple worldwide, and taking up 11% of international health expen-
diture (International Diabetes Federation 2013). The condition
typically develops in late adulthood, usually in people over the
age of 40 years, but younger onset is becoming increasingly more
common. The disease is characterised by poorly regulated blood
glucose levels, which may arise from defects in insulin secretion
(insulin deficiency), or in its action (insulin resistance), or both.
Therefore the aim of treatment is to manage blood glucose levels
to alleviate short-term symptoms and prevent or delay the devel-
opment of long-term complications. Raised glucose in the blood,
known as hyperglycaemia can initially be controlled by lifestyle
management such as changes to diet and exercise, but given the
progressive nature of type 2 diabetes it is likely that most individ-
uals will ultimately require pharmacological intervention as well.
This may initially be with oral hypoglycaemic drugs to increase
the production or uptake of insulin and, if the disease remains
uncontrolled, insulin therapy.
The primary symptoms of type 2 diabetes are increased thirst
and urination, however, not all individuals will experience such
symptoms and therefore many people remain undiagnosed for a
sustained period of time. Undetected hyperglycaemia can have
implications for the outcome of diabetes including greater risk
of developing both macro- and microvascular complications. The
primary microvascular complications to affect people with type 2
diabetes are in relation to the eyes, kidneys and nervous system,
as well as coronary heart disease and major stroke (The Emerging
Risk Factors Collaboration 2010).
Type 2 diabetes prevalence is increasing rapidly worldwide and
is predicted to more than double in the years between 2000 and
2030 (Wild 2004). Although no single causal factor has been at-
tributed to the development of the condition, increasing urbaniza-
tion and ageing populations are strongly linked to global changes
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in diabetes incidence and prevalence. One important risk factor
is a diagnosis of severe mental illness (SMI) such as schizophre-
nia, bipolar disorder and other psychoses, with research suggest-
ing an almost two-fold increased risk of diabetes in people with
SMI compared to those without SMI (Osborn 2008). This in-
creased risk has been linked to a combination of factors including
patient behaviour, in particular physical inactivity and poor diet,
obesity (De Hert 2011) and higher rates of smoking (Lawrence
2009). Alongside lifestyle and behavioural factors, medications
commonly prescribed for SMI are strongly associated with the
development of metabolic abnormalities and weight gain which
significantly increase the risk of type 2 diabetes (De Hert 2011).
The World Health Organization (WHO) recognises mental dis-
order as being an important contributing factor to the global bur-
den of non-communicable diseases such as diabetes and empha-
sises that equitable access to effective programmes and healthcare
interventions is needed (WHO 2013a). As such, the WHO com-
prehensive mental health action plan for 2013 to 2020 states that
developing good-quality mental health services requires the use
of evidence-based protocols and practices. The plan suggests that
health workers must not limit interventions to improving men-
tal health but also attend to the physical health needs of people
with a mental disorder and vice versa (WHO 2013b). In the UK,
the Schizophrenia Commission (The Schizophrenia Commission
2012) and a report from the Royal College of Psychiatrists (Royal
College of Psychiatrists 2009) also recognised that the poorer phys-
ical health of people with SMI needs to be urgently addressed and
include amongst their advice the need for tailored health promo-
tion programmes to help people to manage better their physical
health, including any chronic illnesses.
Considering the importance of lifestyle in themanagement of type
2 diabetes, it is essential that patients possess the necessary skills
to manage their condition. NICE guidelines for type 2 diabetes
(NICE 2008) recommend that structured education is integrated
into routine care and should be offered to all patients. In addi-
tion, the NHS report for the commissioning of mental health and
diabetes services in the UK (NHS Diabetes 2011) clearly states
that people with SMI who develop diabetes should have access
to appropriate diabetes care. However, despite evidence to suggest
that diabetes self-management (DSM) programs have a positive
impact on clinical, lifestyle and psychosocial outcomes (Deakin
2005;Duke 2009; Pal 2013; Steed2003; Steinsbekk 2012;Thorpe
2013), an examination of recent systematic reviews suggests that
many trials either exclude those with SMI or do not specify the
inclusion criteria in relation to SMI. In those that do not exclude
on the basis of mental illness, there is no examination of whether
a diagnosis of SMI has an impact on the effectiveness of such in-
terventions.
For people with a SMI, physical health may be a low priority
(Buhagiar 2011) and motivation to change may be limited, pre-
senting additional challenges for successful self-management. It
cannot therefore be assumed that the findings reported in existing
systematic reviews of DSM interventions will generalise to those
with SMI. A systematic review of DSM for those with schizophre-
nia and schizoaffective disorder found that approaches delivered
in both inpatient and outpatient settings can be effective in man-
aging type 2 diabetes, particularly those that address diet and ex-
ercise behaviour, but concluded that intervention packages need
to be tailored to the unique challenges associated with decreased
cognition and motivation, limited resources, as well as the loss of
energy and weight gain associated with the use of antipsychotics
(Cimo 2012).
Description of the intervention
DSM interventions are complex interventions as they consist of
several interacting components (Craig 2008). Self-management
refers to an individual’s ability to manage the clinical and psy-
chosocial consequences, along with the lifestyle changes inherent
in living with a chronic condition (Barlow 2002). Due to this
broad definition, the content and complexity of DSM interven-
tions varies quite significantly, not only in terms of their aims and
the behaviour/s they target (e.g. self-monitoring of blood glucose,
insulin titration, diet or exercise), but also in terms of their inten-
sity, duration, where the intervention is delivered (i.e. primary or
secondary care), mode of delivery (i.e. group, individual, online),
type and training of the facilitator (i.e. healthcare professional/s
or lay person), the behaviour change techniques used and their
theoretical background. Lorig 2003 has however defined five core
self-management skills: (1) problem solving, (2) decision making,
(3) use of healthcare resources, (4) forming a patient/healthcare
professional partnership and (5) taking action.
Adverse effects of the intervention
There is little evidence to suggest that diabetes self-management
interventions are associated with any adverse effects. However, it
is possible that adverse effects could occur if:
• the content of the DSM intervention is not evidence-based
possibly resulting in patients receiving incorrect information and
training;
• patients misunderstand the information they are given or
are unable to perform the required behaviours;
• patients became anxious as a result of being more engaged,
for example if blood glucose readings are high and patients are
unable to understand why (Peel 2004);
• being more engaged leads to inappropriate use of healthcare
services;
• exercise leads to injury or increased pain and fatigue;
• patients make decisions which are detrimental to their
health and well-being, such as insulin titration that leads to
hypoglycaemia.
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How the intervention might work
The development of self-management interventions has been in-
fluenced by several theories of health behaviour change, including
social cognitive theory (Bandura 1986), the theory of reasoned ac-
tion and planned behaviour (Ajzen 1991), self-regulation theory
(Leventhal 1984) and transtheoretical model (Prochaska 1997).
These theories all identify concepts that predict health behaviour,
primarily focusing on beliefs, attitudes and expectations. The re-
sulting self-management interventions therefore differ in their the-
oretical underpinnings and hence the techniques they adopt to
change behaviour. For example, a diabetes self-management in-
tervention based on social cognitive theory (Bandura 1986) may
seek to reduce carbohydrate intake by increasing diet-related self-
efficacy. Bandura proposed a number of ways in which self-effi-
cacy can be enhanced, including skills mastery where a person
gains confidence by successfully achieving a goal, observation of
someone performing the behaviour and verbal persuasion. These
behaviour change techniques (BCTs) are the ’active ingredients’
which explain how a self-management intervention works.
In response to guidance from theMedical ResearchCouncil (Craig
2008), which acknowledges the need for improved methods of
specifying and reporting complex interventions, the Behaviour
Change Technique Taxonomy (BCTTv1) (Michie 2013) was de-
veloped. The taxonomy provides standardised descriptions of the
different techniques so that a shared language is used in the field
of behaviour change, and links these techniques to published the-
ories of behaviour change. The implementation of the BCTTv1
(Michie 2013) within this systematic review will therefore identify
these active ingredients and provide a cumulative understanding,
across the field of behaviour change, of how diabetes self-manage-
ment interventions work.
In addition to the active ingredients there are a number of other
key features of a behaviour change intervention including the be-
haviour or behaviours they aim to target (i.e. diet, exercise, self-
monitoring), duration, intensity, setting, mode of delivery and
type and training facilitator, all of which can influence the effi-
cacy and replicability of an intervention (Hoffman 2014). Figure
1 presents a simplified schematic representation of the concep-
tual framework for DSMwhich acknowledges the complex nature
of these interventions, along with the most well-established self-
management behaviour change techniques included in these in-
terventions.
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Figure 1. Schematic representation of diabetes self-management
Why it is important to do this review
Whilst there is some evidence to indicate statistically and clinically
significant benefits for DSM interventions in the general popula-
tion (Deakin 2005; Duke 2009; Pal 2013; Steed 2003; Steinsbekk
2012; Thorpe 2013), there is little evidence that these interven-
tions are effective in changing outcomes for people with SMI and
type 2 diabetes. This review aims to broaden the inclusion criteria
of a previous systematic review (Cimo 2012) to SMIs other than
schizophrenia and schizoaffective disorder and other outcomes in-
cluding patient-reported and socioeconomic outcomes.
This review will not only evaluate the effects of diabetes self-man-
agement interventions for people with SMI and type 2 diabetes,
but will also provide us with the opportunity to describe, using es-
tablished reporting systems, the active components of these inter-
ventions and the theoretical frameworks within which they were
developed. The Medical Research Council (MRC) guidelines for
developing complex interventions (Craig 2008) and the Consoli-
dated Standards of Reporting Trials (CONSORT) statement for
randomised controlled trials (RCTs) of non-pharmacological in-
terventions (Boutron 2008) both acknowledge the need for im-
proved methods of specifying and reporting intervention content.
In addition to the BCTTv1 (Michie 2013), a coding system to
assess the different ways that behavioural interventions have em-
ployed theory (Michie 2010) will also be applied. This theoreti-
cal coding system will enable an assessment of how, and to what
extent, theory has been used to develop the intervention. Use of
these coding systems will therefore be helpful in systematically
identifying and documenting the content of DSM interventions
for people with SMI and type 2 diabetes as well as establish which
components and theories are most effective. By undertaking sub-
group analysis this review will aim to identify not only if interven-
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tion effects vary by intervention characteristics, but also by patient
characteristics, in order to establish what kind of self-management
intervention works best for whom and under what conditions.
O B J E C T I V E S
To assess the effects of diabetes self-management (DSM) interven-
tions for people with type 2 diabetes with severe mental illness
(SMI).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include RCTs.
Types of participants
Adult individuals with SMI and type 2 diabetes. Adults partici-
pants will be defined as those aged 18 years and over.
Diagnostic criteria
Diagnosis of type 2 diabetes should have been consistent with the
standard classification criteria valid at the time of the trial (for
example ADA 1999; ADA2008;WHO1998).We plan to subject
type 2 diabetes mellitus diagnostic criteria to a sensitivity analysis.
SMI will be defined as psychosis, schizophrenia, schizoaffective
disorder, bipolar disorder, personality disorder, or depression with
psychotic features, however diagnosed.
Types of interventions
Intervention
Interventions that are targeted to improve the self-management
of type 2 diabetes mellitus; this could include interventions that
target self-monitoring of blood glucose, diet or exercise behaviour.
This may or may not include the self-management of SMI but
interventions which focus solely on the management of SMI will
be excluded. The intervention can be of any duration.
Comparator
The comparison group will be either another active intervention
or usual/standard care.
Exclusions
Any intervention which:
• includes only participants with type 1 diabetes;
• includes participants without SMI;
• involves participants under the age of 18 years, including
trials that include both adults and children;
• are targeted at healthcare professionals;
• focuses exclusively on self-management of SMI.
Studies that include both type 1 and 2 diabetes will only be in-
cluded if results can be extracted for participants with type 2 dia-
betes.
Types of outcome measures
Primary outcomes
• Self-care behaviours.
• Diabetes-related complications.
• Adverse events.
Secondary outcomes
• All-cause mortality.
• Health-related quality of life.
• Diabetes knowledge.
• Self-efficacy.
• Progression of severe mental illness.
• HbA1c.
• Body mass index (BMI).
• Weight.
• Blood pressure.
• Change in medication or intensity of drug treatment.
• Socioeconomic effects.
Method of outcome measurement
• Diabetes-related complications defined as vascular
complications (angina pectoris, myocardial infarction, stroke or
peripheral vascular disease), neuropathy, nephropathy,
retinopathy, diabetic foot and lower limb amputation and heart
failure.
• Glycaemic control will be measured via HbA1c.
• Adverse events of the intervention defined as
hypoglycaemia, pain, fatigue and anxiety.
• All-cause mortality defined as death from any cause.
• Health-related quality of life evaluated with a validated
generic or disease specific instrument such as the SF-36®
(McHorney 1993; Ware 1992) or Diabetes Health Profile
(DHP) (Meadows 2000).
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• Self-care behaviours evaluated with a validated instrument
such as the Summary of Diabetes Self-care Activities (SDSCA)
measure (Toobert 2000).
• Diabetes knowledge evaluated with a validated instrument
such as the Brief Diabetes Knowledge Test (Fitzgerald 1998).
• General or diabetes-specific self-efficacy evaluated with a
validated instrument such as the Diabetes Empowerment Scale
(Anderson 2000).
• Progression of severe mental illness assessed using a disease-
specific such as the Positive and Negative Syndrome Scale (Kay
1987) or generic such as the Clinical Global Impressions scale
(Busner 2007) or Health of the Nation Outcome Scale (Wing
1998).
• BMI in kg/m² or waist-to-hip ratio as a ratio.
• Weight in kg or lbs.
• Systolic and diastolic blood pressure in mm Hg.
• Intensity of type 2 diabetes treatment defined as an increase
in medication dose or the introduction of an additional drug.
• Intensity of SMI treatment defined as an increase in
medication dose or the introduction of an additional drug.
• Socioeconomic effects: direct costs defined as admission/
readmission rates, average length of stay, visits to general
practitioner, accident/emergency visits; indirect costs: defined as
resources lost due to illness by patient or their family member.
Timing of outcome measurement
The timing of outcome measurement will be classified as short,
medium and long term. For any meta-analysis performed, data
from the longest follow-up will be used. Short-term follow-up will
be defined as measurement taken within one month of the end of
the intervention period and will therefore capture the immediate
effects of the intervention;medium-term follow-upwill be defined
as between one and six months post intervention and long-term
follow-up six months and longer.
’Summary of findings’ table
We will present a ’Summary of findings’ table reporting the fol-
lowing outcomes.
1. Diabetes-related complications.
2. All-cause mortality.
3. Adverse events.
4. Health-related quality of life.
5. Self-care behaviours.
6. HbA1c.
7. Socioeconomic effects.
Search methods for identification of studies
Electronic searches
We will search the following sources from inception of each
database to the specified date and will place no restrictions on the
language of publication.
• The Cochrane Library.
◦ CDSR
◦ CENTRAL
◦ DARE
◦ HTA
• MEDLINE.
• EMBASE.
• PsycINFO.
• Allied and Complimentary Medicine Database (AMED).
• Health Technology Assessment (HTA).
• NHS Economic Evaluations Database (NHS EED).
• CINAHL Plus.
• ICTRP trial register (http://apps.who.int/trialsearch/)
◦ Australian New Zealand Clinical Trials Registry
◦ ClinicalTrials.gov
◦ EU Clinical Trials Register
◦ ISRCTN
◦ Brazilian Clinical Trials Registry
◦ Chinese Clinical Trial Registry
◦ Clinical Trials Registry - India
◦ Clinical Research Information Service - Republic of
Korea
◦ Cuban Public Registry of Clinical Trials
◦ German Clinical Trials Register
◦ Iranian Registry of Clinical Trials
◦ Japan Primary Registries Network
◦ Pan African Clinical Trial Registry
◦ Sri Lanka Clinical Trials Registry
◦ The Netherlands National Trial Register
◦ Thai Clinical Trials Register
Wewill continuously apply aMEDLINE (viaOvid SP) email alert
service to identify newly published studies using the same search
strategy as described for MEDLINE (for details on search strate-
gies see Appendix 1). After supplying the final review draft for
editorial approval, the Cochrane Metabolic and Endocrine Disor-
ders Group (CMED) will perform a complete update search on
all databases available at the editorial office and send the results to
the review authors. Should we identify new studies for inclusion
we will evaluate these, incorporate findings in our review and re-
submit another review draft (Beller 2013).
If we detect additional relevant key words during any of the elec-
tronic or other searches, wewill modify the electronic search strate-
gies to incorporate these terms and document the changes.
Searching other resources
We will try to identify other potentially eligible trials or ancillary
publications by searching the reference lists of retrieved articles in-
cluding trials, (systematic) reviews, meta-analyses and health tech-
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nology assessment reports. Unpublished literature will be searched
for using the following databases.
• BASE: Bielefeld Academic Research Engine (http://
www.base-search.net/).
• Open Grey (http://www.opengrey.eu/).
• NHS Evidence (http://www.evidence.nhs.uk/).
• UK Clinical Research Network Study Portfolio (http://
public.ukcrn.org.uk/search/).
Data collection and analysis
Selection of studies
Two review authors (HM, MH) will independently scan the ab-
stract, title, or both, of every record retrieved, to determine which
studies should be assessed further. We will investigate all poten-
tially-relevant articles as full text. We will resolve any discrepancies
through consensus or recourse to a third review author (CF). If
resolving disagreement is not possible, the article will be added
to those ’awaiting assessment’ and we will contact study authors
for clarification. We will present an adapted PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-Analyses) dia-
gram of study selection (Liberati 2009).
Data extraction and management
For studies that fulfil inclusion criteria, two review authors (HM,
KM) will independently extract key participant and intervention
characteristics and report data on efficacy outcomes and adverse
events using standard data extraction templates as supplied by the
CMED, with any disagreements to be resolved by discussion, or,
if required, by consultation with a third review author(AS).
We will provide information including trial identifier about po-
tentially relevant ongoing studies in the table ’Characteristics of
ongoing studies’. We will try to find the protocol of each included
study and will report primary, secondary and other outcomes in
comparison with data in publications in a joint appendix ’Matrix
of study endpoint (publications and trial documents)’.
We will email all authors of included studies to enquire whether
they are willing to answer questions regarding their trials. We will
present the results of this survey in an appendix. Thereafter, wewill
seek relevant missing information on the trial from the primary
author(s) of the article, if required.
Both the intervention and comparator group will be coded for the
use of theory and behaviour change techniques. This will enable
articles to be grouped according to the unique components found
within the diabetes self-management (DSM) intervention:
Use of theory
A theory coding scheme has been developed which assesses how
and to what extent theory has been used to develop an interven-
tion (Michie 2010). The coding scheme consists of 19 items each
requiring a yes, no or do not know response. These 19 questions
are classified into six categories: (i) is theory mentioned, (ii) are the
relevant theoretical constructs targeted, (iii) is theory used to select
recipients or tailor an intervention, (iv) are the relevant theoretical
constructs measured, (v) is theory tested and (vi) has theory been
refined. For the purposes of any statistical analysis, if the theo-
retical basis for the intervention group is the same as the control
group, the intervention will be coded as not having a theoretical
basis (except for descriptive purposes); as theory would be unable
to explain the difference in the effect size between the two groups.
Behaviour change techniques
The recently published behaviour change technique taxonomy
(BCTTv1) (Michie 2013) will be used to code both the interven-
tion and control groups. The behaviour change technique (BCT)
will either be coded as being present within the intervention and
control group, in the intervention group only or within the control
group only. A description will be provided of the most common
and consistently implemented techniques. For the purposes of any
statistical analysis only those BCTs which are unique to the inter-
vention groups will be analysed to enable identification of those
techniques that could be attributed to differences in outcomes be-
tween groups. Those involved in the extraction and coding of data
on BCTs will have undertaken the required BCTT training. If the
same BCT is employed within both the intervention and control
group, the intervention will be coded as not containing the BCT
(except for descriptive purposes); as the BCT would be unable to
explain any differences in effect size between the two conditions.
Dealing with duplicate and companion publications
In the event of duplicate publications, companion documents or
multiple reports of a primary study, we will maximise yield of in-
formation by collating all available data and use the most com-
plete data set aggregated across all known publications. In case of
doubt, the publication reporting the longest follow-up associated
with our primary or secondary outcomes will be given priority.
Assessment of risk of bias in included studies
Two review authors (HM, JJ) will assess the risk of bias of each
included study independently. We will resolve disagreements by
consensus, or by consultation with a third author (MH). We will
assess risk of bias using the Cochrane Collaboration’s tool for as-
sessment of risk of bias (Higgins 2011a; Higgins 2011b) using the
following criteria.
• Random sequence generation (selection bias).
7Self-management interventions for type 2 diabetes in adult people with severe mental illness (Protocol)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• Allocation concealment (selection bias).
• Blinding (performance bias and detection bias), blinding of
participants and personnel assessed separately from blinding of
outcome assessment.
• Incomplete outcome data (attrition bias).
• Selective reporting (reporting bias).
• Other bias.
We will judge ’Risk of bias’ criteria as ’low risk’, ’high risk’ or
’unclear risk’ and will evaluate individual bias items as described
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011a).We will present a ’Risk of bias’ graph and a ’Risk
of bias summary’ figure. We will assess the impact of individual
bias domains on study results at the endpoint and study levels. In
case of high risk of selection bias, all endpoints investigated in the
associated study will be marked as ’high risk’.
For performance bias (blinding of participants and personnel) and
detection bias (blinding of outcome assessors) we will evaluate the
risk of bias separately for each outcome (Hróbjartsson 2013). We
will note whether outcomes were measured subjectively or objec-
tively, for example, if body weight was measured by participants
or study personnel.
We will consider the implications of missing outcome data from
individual participants per outcome such as high drop-out rates
(e.g. above 15%) or disparate attrition rates (e.g. difference of 10%
or more between study arms).
We will assess outcome reporting bias by integrating the results of
an appendix ’Examination of outcome reporting bias’ (Kirkham
2010), an appendix ’Matrix of study endpoints (publications and
trial documents)’ and section ’Outcomes (outcomes reported in
abstract of publication)’ of the ’Characteristics of included studies’
table. This analysis will form the basis of the judgement of selective
reporting (reporting bias).
We define the following endpoints as subjective outcomes.
• Health-related quality of life.
• Self-care behaviours.
• Diabetes knowledge.
• Self-efficacy.
• Adverse events, depending on measurement.
• Body mass index (BMI), depending on measurement.
• Weight, depending on measurement.
• Change in medication or intensity of drug treatment,
depending on measurement.
We define the following outcomes as objective outcomes.
• HbA1c.
• All-cause mortality.
• Diabetes-related complications.
• Body mass index (BMI), depending on measurement.
• Weight, depending on measurement.
• Blood pressure.
• Change in medication or intensity of drug treatment,
depending on measurement.
• Socioeconomic effects.
Measures of treatment effect
We will express dichotomous outcomes as risk ratios, with 95%
confidence intervals (CI). For continuous outcomes where the
same measurement scale has been used e.g. HbA1c, the measure
of treatment effect will be the mean difference or difference in
means, with 95% CI. For continuous outcomes where different
measurement scales have been used, such as quality of life, the
measure of treatment effect will be standardised mean difference
(SMD). The definition of SMD used in Cochrane reviews is the
effect size known in social science as Hedges’ g (adjusted) (Hedges
1985). If Hedge’s g is not reported it will be calculated as the dif-
ference between the two means (intervention and control) divided
by the pooled standard deviation. If this is not possible, the results
of each study will be described in a narrative synthesis. We will
express time-to-event data as hazard ratios (HRs) with 95% CIs.
Unit of analysis issues
We will take into account the level at which randomisation oc-
curred, such as cross-over trials, cluster-randomised trials andmul-
tiple observations for the same outcome.
Data from cross-over trials will be extracted for the intervention
and control group at baseline and at the time point immediately
prior to cross-over. In case of a unit of analysis error occurrence in
cluster-randomised controlled trials, we will adjust for the design
effect by reducing the size of the trial to its “effective sample size”
(Rao 1992). This is calculated by dividing the original sample size
by the ’design effect’. The design effect is 1 + (M - 1) * ICC,
where M is the average cluster size and ICC is the intra-cluster
correlation coefficient. For dichotomous data, both the number
of participants and the number experiencing the event will be
divided by the design effect. For continuous data, only the sample
sizes will be reduced; means and standard deviations will remain
unchanged (Higgins 2011a).
Dealing with missing data
We will obtain missing data from authors, if feasible, and carefully
evaluate important numerical data such as screened, randomised
participants as well as intention-to-treat (ITT), and as-treated and
per-protocol populations. We will investigate attrition rates, e.g.
drop-outs, losses to follow-up and withdrawals, and critically ap-
praise issues of missing data or using imputation methods (e.g. last
observation carried forward (LOCF), mean imputation, imputing
based on predicted values from a regression analysis).
Where standard deviations for outcomes are not reported and we
do not receive information from study authors, we will impute
these values by assuming the standard deviation of the missing
outcome to be the average of the standard deviations from those
studies where this information was reported. We will investigate
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the impact of imputation on meta-analyses by means of sensitivity
analysis.
If authors fail to respond within one month of first contact, a
second attempt will be made. If after two months no response is
received data will be recorded as missing.
Assessment of heterogeneity
In the event of substantial clinical, methodological or statistical
heterogeneity, we will not report study results as the pooled effect
estimate in a meta-analysis. We will identify heterogeneity (incon-
sistency) by visual inspection of the forest plots and by using a
standard Chi2 test with a significance level of α = 0.1. In view
of the low power of this test, we will also consider the I2 statis-
tic, which quantifies inconsistency across studies to assess the im-
pact of heterogeneity on themeta-analysis (Higgins 2002; Higgins
2003); where an I2 statistic of 75% or more indicates a consid-
erable level of heterogeneity (Higgins 2011a). We expect type of
diabetes treatment (i.e. insulin versus non-insulin dependent type
2 diabetes) and SMI diagnosis to introduce clinical heterogeneity.
Assessment of reporting biases
If we include 10 studies or more that investigate a particular out-
come, we will use funnel plots to assess small-study effects. Owing
to several possible explanations for funnel plot asymmetry, we will
interpret results carefully (Sterne 2011).
Data synthesis
Unless there is good evidence for homogeneous effects across stud-
ies, we will summarise primarily low risk of bias data by means of
a random-effects model (Wood 2008). We will interpret random-
effectsmeta-analyses with due consideration of the whole distribu-
tion of effects, ideally by presenting a prediction interval (Higgins
2009). A prediction interval specifies a predicted range for the true
treatment effect in an individual study and will be calculated if
there are at least three studies (Riley 2011). In addition, we will
perform statistical analyses according to the statistical guidelines
contained in the latest version of the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011a).
Quality of evidence
We will present the overall quality of the evidence for each out-
come according to the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) approach, which takes
into account issues not only related to internal validity (risk of bias,
inconsistency, imprecision, publication bias), but also to external
validity such as directness of results. Two review authors (HM,
KM)will independently rate the quality for each outcome.Wewill
present a summary of the evidence in a ’Summary of findings’ ta-
ble, which provides key information about the best estimate of the
magnitude of the effect, in relative terms and absolute differences
for each relevant comparison of alternativemanagement strategies,
numbers of participants and studies addressing each important
outcome and the rating of the overall confidence in effect estimates
for each outcome. We will create the ’Summary of findings’ table
based on the methods described in chapter 11 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011a).
We will present results on the outcomes as described in the Types
of outcome measures section. If meta-analysis is not possible, we
will present results in a narrative ’Summary of findings’ table.
In addition, we will establish an appendix ’Checklist to aid consis-
tency and reproducibility of GRADE assessments’ (Meader 2014)
to help with standardisation of ’Summary of findings’ tables.
Subgroup analysis and investigation of heterogeneity
Patient education and self-management are an integral part of di-
abetes care. Patients have a right to receive education about their
diabetes and the treatment options, as well as information and
training in how they can best manage their condition. Clearly
the efficacy of diabetes self-management interventions for people
with SMI is important, but it is equally important to identify the
optimal content and delivery methods as well as the participant
characteristics which lead to the most improved outcomes. Sub-
group analyses will therefore be performed in order to establish if
intervention effects vary with different participant populations or
intervention characteristics. These comparisons will be hypothesis
generating only.
• Age.
• Gender.
• Disease duration at baseline for both type 2 diabetes and
SMI.
• Insulin-treated versus non-insulin treated type 2 diabetes.
• SMI treatment (i.e. antipsychotic medication versus no
antipsychotic medication, typical (first generation) antipsychotic
medication versus atypical (second generation) antipsychotic
medication, olanzapine or clozapine treatment versus other
antipsychotic treatment).
• SMI diagnosis (i.e. psychosis, schizophrenia, schizoaffective
disorder, bipolar disorder, personality disorder or depression with
psychotic features).
• Targeted behaviour (e.g. self-monitoring, self-adaption of
drug/insulin, exercise, diet).
• HbA1c at baseline.
• Behaviour change techniques used.
• Use of a theory to inform the intervention.
• Intensity of the intervention.
• Intervention setting (i.e. primary, secondary care or
community).
Sensitivity analysis
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We will perform sensitivity analyses in order to explore the influ-
ence of the following factors (when applicable) on effect sizes.
• Restricting the analysis to published studies.
• Restricting the analysis by taking into account risk of bias,
as specified in the section ’Assessment of risk of bias in included
studies’.
• Restricting the analysis to very long or large studies to
establish the extent to which they dominate the results.
• Restricting the analysis to studies using the following filters:
diagnostic criteria, imputation, language of publication, source
of funding (industry versus other), country.
We will also test the robustness of the results by repeating the anal-
ysis using different measures of effect size (RR, OR etc.) and dif-
ferent statistical models (fixed-effect and random-effects models).
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A P P E N D I C E S
Appendix 1. Search strategies
Search terms and databases
Unless otherwise stated, search terms are free text terms.
Abbreviations:
’$’: stands for any character; ’?’: substitutes one or no character; adj: adjacent (i.e. number of words within range of search term); exp:
exploded MeSH; MeSH: medical subject heading (MEDLINE medical index term); pt: publication type; sh: MeSH; tw: text word
The Cochrane Library
# 1MeSH descriptor Diabetes mellitus, type 2 explode all trees
# 2(MODY in All Text or NIDDM in All Text or TDM2 in All Text or TD2 in All Text)
# 3((non in All Text and insulin* in All Text and depend* in All Text) or (noninsulin* in All Text and depend* in All Text) or (non
in All Text and insulindepend* in All Text) or noninsulindepend* in All Text)
# 4(typ? in All Text and (2 in All Text near/6 diabet* in All Text))
# 5(typ? in All Text and (II in All Text near/6 diabet* in All Text))
# 6(adult* in All Text near/6 diabet* in All Text)
# 7(matur* in All Text near/6 diabet* in All Text)
# 8(late in All Text near/6 diabet* in All Text)
# 9(slow in All Text near/6 diabet* in All Text)
# 10(stabl* in All Text near/6 diabet* in All Text)
# 11(#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10)
# 12MeSH descriptor Diabetes insipidus explode all trees
# 13(diabet* in All Text and insipidus in All Text)
# 14(#12 or #13)
# 15(#11 and not #14)
# 16MeSH descriptor Mental disorders explode all trees
# 17MeSH descriptor Psychotic disorders explode all trees
# 18MeSH descriptor Mood disorders explode all trees
# 19MeSH descriptor Personality disorders explode all trees
# 20MeSH descriptor Bipolar disorder explode all trees
# 21MeSH descriptor Schizophrenia explode all trees
# 22((mental in All Text near/6 disorder* in All Text) or (mental in All Text near/6 illness in All Text))
# 23(schizo* in All Text or psycho* in All Text)
# 24((bipolar in All Text near/6 disorder* in All Text) or (affective in All Text near/6 disorder* in All Text) or (personality in All Text
near/6 disorder* in All Text))
# 25MeSH descriptor Depression explode all trees
# 26depression* in All Text
# 27(#16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26)
# 28(#15 and #27)
# 29MeSH descriptor Patient education as topic explode all trees
# 30MeSH descriptor Patient compliance explode all trees
# 31MeSH descriptor Self care explode all trees
# 32MeSH descriptor Health promotion explode all trees
# 33MeSH descriptor Behavior therapy explode all trees
# 34MeSH descriptor Health behavior explode all trees
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(Continued)
# 35MeSH descriptor Program evaluation explode all trees
# 36MeSH descriptor Life style explode all trees
# 37((self in All Text near/6 care in All Text) or (self in All Text near/6 monitoring in All Text) or (self in All Text near/6 management
in All Text))
# 38((patient in All Text near/6 education* in All Text) or (patient in All Text near/6 compliance in All Text) )
# 39((health in All Text near/6 promotion* in All Text) or (health in All Text near/6 behavior* in All Text) or (health in All Text near/
6 behaviour* in All Text))
# 40(program in All Text near/6 evaluation* in All Text)
# 41((behavioral in All Text near/6 intervention* in All Text) or (behavioral in All Text near/6 therap* in All Text) or (behavioral in
All Text near/6 treatment* in All Text) or (behavioral in Abstract near/6 chang* in Abstract))
# 42((behavioural in All Text near/6 treatment* in All Text) or (behavioural in All Text near/6 therap* in All Text) or (behavioural in
All Text near/6 intervention* in All Text) or (behavioural in All Text near/6 chang* in All Text))
# 43((psychosocial in All Text near/6 intervention* in All Text) or (psychosocial in All Text near/6 treatment* in All Text) or
(psychosocial in All Text near/6 therap* in All Text))
# 44((psycho-social in All Text near/6 intervention* in All Text) or (psycho-social in All Text near/6 treatment* in All Text) or (psycho-
social in All Text near/6 therap* in All Text))
# 45(adherence in All Text or (c in All Text and ompliance in All Text))
# 46((lifestyle in All Text near/6 intervention* in All Text) or (lifestyle in All Text near/6 chang* in All Text))
# 47((life-style in All Text near/6 intervention* in All Text) or (life-style in All Text near/6 chang* in All Text))
# 48MeSH descriptor Weight loss explode all trees
# 49((weight in All Text near/6 management in All Text) or (weight in All Text near/6 los* in All Text) or (weight in All Text near/6
reduction* in All Text))
# 50(#29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #
46 or #47 or #48 or #49)
# 51(#28 and #50)
MEDLINE
1 exp Diabetes Mellitus, Type 2/
2 (MODY or NIDDM or T2DM or T2D).tw,ot.
3 (non insulin$ depend$ or noninsulin$ depend$ or noninsulin?depend$ or non insulin?depend$).tw,ot.
4 ((typ? 2 or typ? II or typ?2 or typ?II) adj3 diabet$).tw,ot.
5 (((late or adult$ or matur$ or slow or stabl$) adj3 onset) and diabet$).tw,ot.
6 or/1-5
7 exp Diabetes Insipidus/
8 diabet$ insipidus.tw,ot.
9 7 or 8
10 6 not 9
11 exp Mental Disorders/
12 exp Psychotic disorders/
13 exp Mood disorders/
14 exp Personality disorders/
15 exp Bipolar disorders/
16 exp Schizophrenia/
17 (mental adj6 (disorder* or illness)).tw,ot.
18 (schizo* or psycho*).tw,ot.
19 ((bipolar or affective or personality) adj6 disorder*).tw,ot.
20 exp Depression/
21 depression*.tw,ot.
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(Continued)
22 or/11-21
23 10 and 22
24 exp Patient Education as Topic/
25 exp Patient Compliance/
26 exp Self Care/
27 exp Health Promotion/
28 exp Behavior Therapy/
29 exp Health Behavior/
30 exp Program Evaluation/
31 exp Life style/
32 (self adj6 (care or management or monitoring)).tw,ot.
33 (patient adj6 (education* or compliance)).tw,ot.
34 (health adj6 (promotion* or behavio?r*)).tw,ot.
35 (program adj6 evaluation*).tw,ot.
36 (behavio?ral adj6 (intervention* or therap* or treatment* or chang*)).tw,ot.
37 ((psychosocial or psycho-social) adj6 (intervention* or treatment* or therap*)).tw,ot.
38 (adherence or compliance).mp.
39 ((lifestyle or life style) adj6 (intervention* or chang*)).tw,ot.
40 exp Weight Loss/
41 (weight adj6 (management or los* or reduction*)).tw,ot.
42 (lifestyle adj6 (intervention* or chang*)).tw,ot.
43 or/24-42
44 23 and 43
45 randomized controlled trial.pt.
46 controlled clinical trial.pt.
47 randomi?ed.ab.
48 placebo.ab.
49 drug therapy.fs.
50 randomly.ab.
51 trial.ab.
52 groups.ab.
53 or/45-52
54 Meta-analysis.pt.
55 exp Technology Assessment, Biomedical/
56 exp Meta-analysis/
57 exp Meta-analysis as topic/
58 hta.tw,ot.
59 (health technology adj6 assessment$).tw,ot.
60 (meta analy$ or metaanaly$ or meta?analy$).tw,ot.
61 (search* adj10 (medical databas*or medline or pubmed or embase or cochrane or cinahl or psycinfo or psyclit or healthstar or
biosis or current content*)).tw,ot.
62 (systematic adj3 review*).tw,ot.
63 or/54-62
64 53 or 63
65 (comment or editorial or historical-article).pt.
66 64 not 65
67 44 and 66
EMBASE
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(Continued)
1 exp Diabetes Mellitus, Type 2/
2 (MODY or NIDDM or T2D or T2DM).tw,ot.
3 ((typ? 2 or typ? II or typ?II or typ?2) adj3 diabet*).tw,ot.
4 (obes* adj3 diabet*).tw,ot.
5 (non insulin* depend* or non insulin?depend* or noninsulin* depend* or noninsulin?depend*).tw,ot.
6 ((adult* or matur* or late or slow or stabl*) adj3 diabet*).tw,ot.
7 or/1-6
8 exp diabetes insipidus/
9 diabet* insipidus.tw,ot.
10 8 or 9
11 7 not 10
12 exp mental disease/
13 exp psychosis/
14 exp mood disorder/
15 exp personality disorder/
16 exp bipolar disorder/
17 exp schizophrenia/
18 exp depression/
19 (mental adj6 (disorder* or disease* or illness)).tw,ot.
20 (schizo* or psycho*).tw,ot.
21 ((bipolar or affective or personality) adj6 (diseas* or disorder)).tw,ot.
22 depression*.tw,ot.
23 or/12-22
24 11 and 23
25 exp patient education/
26 exp patient compliance/
27 exp self care/
28 exp health promotion/
29 exp behavior therapy/
30 *health care quality/
31 exp lifestyle/
32 (self adj6 (care or management or monitoring)).tw,ot.
33 (patient adj6 (education* or compliance)).tw,ot.
34 (health adj6 (promotion* or behavio?r*)).tw,ot.
35 (program adj6 evaluation*).tw,ot.
36 (behavio?ral adj6 (intervention* or therap* or treatment* or chang*)).tw,ot.
37 ((psychosocial or psyco social) adj6 (intervention* or treatment* or therap*)).tw,ot.
38 (adherence or compliance).mp.
39 ((lifestyle or life style) adj6 (intervention* or chang*)).tw,ot.
40 exp weight reduction/
41 (weight adj6 (management or los* or reduction*)).tw,ot.
42 or/25-41
43 24 and 42
44 exp Randomized Controlled Trial/
45 exp Controlled Clinical Trial/
46 exp Clinical Trial/
47 exp Comparative Study/
48 exp Drug comparison/
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(Continued)
49 exp Randomization/
50 exp Crossover procedure/
51 exp Double blind procedure/
52 exp Single blind procedure/
53 exp Placebo/
54 exp Prospective Study/
55 ((clinical or control$ or comparativ$ or placebo$ or prospectiv$ or randomi?ed) adj3 (trial$ or stud$)).ab,ti.
56 (random$ adj6 (allocat$ or assign$ or basis or order$)).ab,ti.
57 ((singl$ or doubl$ or trebl$ or tripl$) adj6 (blind$ or mask$)).ab,ti.
58 (cross over or crossover).ab,ti.
59 or/44-58
60 exp meta analysis/
61 (metaanaly$ or meta analy$ or meta?analy$).ab,ti,ot.
62 (search$ adj10 (medical database$ or medline or pubmed or embase or cochrane or cinahl or psycinfo or psyclit or healthstar or
biosis or current content$ or systematic$)).ab,ti,ot.
63 (review* adj6 systematic).tw,ot.
64 exp Literature/
65 exp Biomedical Technology Assessment/
66 hta.tw,ot.
67 (health technology adj6 assessment$).tw,ot.
68 or/60-67
69 59 or 68
70 (comment or editorial or historical-article).pt.
71 69 not 70
72 43 and 71
PsycINFO
1 (MODY or NIDDM or T2DM or T2D).tw,ot.
2 (non insulin$ depend$ or noninsulin$ depend$ or noninsulin?depend$ or non insulin?depend$).tw,ot.
3 ((typ? 2 or typ? II or typ?2 or typ?II) adj3 diabet$).tw,ot.
4 (((late or adult$ or matur$ or slow or stabl$) adj3 onset) and diabet$).tw,ot.
5 or/1-4
6 exp Diabetes Insipidus/
7 diabet$ insipidus.tw,ot.
8 6 or 7
9 5 not 8
10 exp Mental Disorders/
11 exp Mood disorders/
12 exp Personality disorders/
13 exp Schizophrenia/
14 (mental adj6 (disorder* or illness)).tw,ot.
15 (schizo* or psycho*).tw,ot.
16 ((bipolar or affective or personality) adj6 (disorder* or illness)).tw,ot.
17 exp Depression/
18 depression*.tw,ot.
19 or/10-18
20 9 and 19
21 exp Self Care/
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22 exp Health Promotion/
23 exp Behavior Therapy/
24 exp Health Behavior/
25 exp Program Evaluation/
26 (self adj6 (care or management or monitoring)).tw,ot.
27 (patient adj6 (education* or compliance)).tw,ot.
28 (health adj6 (promotion* or behavio?r*)).tw,ot.
29 (program adj6 evaluation*).tw,ot.
30 (behavio?ral adj6 (intervention* or therap* or treatment* or chang*)).tw,ot.
31 ((psychosocial or psycho-social) adj6 (intervention* or treatment* or therap*)).tw,ot.
32 (adherence or compliance).mp.
33 ((lifestyle or life style) adj6 (intervention* or chang*)).tw,ot.
34 exp Weight Loss/
35 (weight adj6 (management or los* or reduction*)).tw,ot.
36 or/21-35
37 20 and 36
38 randomi?ed.ab.
39 placebo.ab.
40 randomly.ab.
41 trial.ab.
42 groups.ab.
43 or/38-42
44 exp Meta-analysis/
45 hta.tw,ot.
46 (health technology adj6 assessment$).tw,ot.
47 (meta analy$ or metaanaly$ or meta?analy$).tw,ot.
48 (search* adj10 (medical databas*or medline or pubmed or embase or cochrane or cinahl or psycinfo or psyclit or healthstar or
biosis or current content*)).tw,ot.
49 (systematic adj3 review*).tw,ot.
50 or/44-49
51 43 or 50
52 37 and 51
AMED
1. exp diabetes mellitus type 2/
2. (MODY or NIDDM or T2DM or T2D).mp. [mp=abstract, heading words, title]
3. (non insulin$ depend$ or noninsulin$ depend$ or noninsulin?depend$ or non insulin?depend$).mp. [mp=abstract, heading words,
title]
4. ((typ? 2 or typ? II or typ?2 or typ?II) adj3 diabet$).mp. [mp=abstract, heading words, title]
5. (((late or adult$ or matur$ or slow or stabl$) adj3 onset) and diabet$).mp. [mp=abstract, heading words, title]
6. 1 or 2 or 3 or 4 or 5
7. exp Mental disorders/
8. (mental adj6 (disorder* or illness)).mp. [mp=abstract, heading words, title]
9. (schizo* or psycho*).mp. [mp=abstract, heading words, title]
10. ((bipolar or affective or personality) adj6 disorder*).mp. [mp=abstract, heading words, title]
11. exp depression/
12. depression*.mp. [mp=abstract, heading words, title]
13. 7 or 8 or 9 or 10 or 11 or 12
14. 6 and 13
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15. exp patient education/
16. exp self care/
17. health education/
18. exp health promotion/
19. exp health behavior/
20. exp program evaluation/
21. exp life style/
22. (self adj6 (care or management or monitoring)).mp. [mp=abstract, heading words, title]
23. (patient adj6 (education* or compliance)).mp. [mp=abstract, heading words, title]
24. (health adj6 (promotion* or behavio?r*)).mp. [mp=abstract, heading words, title]
25. (program adj6 evaluation*).mp. [mp=abstract, heading words, title]
26. (behavio?ral adj6 (intervention* or therap* or treatment* or chang*)).mp. [mp=abstract, heading words, title]
27. ((psychosocial or psycho-social) adj6 (intervention* or treatment* or therap*)).mp. [mp=abstract, heading words, title]
28. (adherence or compliance).mp. [mp=abstract, heading words, title]
29. ((lifestyle or life style) adj6 (intervention* or chang*)).mp. [mp=abstract, heading words, title]
30. exp Weight loss/
31. (weight adj6 (management or los* or reduction*)).mp. [mp=abstract, heading words, title]
32. (lifestyle adj6 (intervention* or chang*)).mp. [mp=abstract, heading words, title]
33. 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32
34. 14 and 33
35. exp clinical trials/
36. exp comparative study/
37. exp random allocation/
38. exp Placebos/
39. exp prospective studies/
40. ((clinical or control$ or comparativ$ or placebo$ or prospectiv$ or randomi?ed) adj3 (trial$ or stud$)).mp. [mp=abstract, heading
words, title]
41. (random$ adj6 (allocat$ or assign$ or basis or order$)).mp. [mp=abstract, heading words, title]
42. ((singl$ or doubl$ or trebl$ or tripl$) adj6 (blind$ or mask$)).mp. [mp=abstract, heading words, title]
43. (cross over or crossover).mp. [mp=abstract, heading words, title]
44. 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43
45. exp Meta analysis/
46. (metaanaly$ or meta analy$ or meta?analy$).mp. [mp=abstract, heading words, title]
47. (review* adj6 systematic).mp. [mp=abstract, heading words, title]
48. (search* adj10 (medical databas*or medline or pubmed or embase or cochrane or cinahl or psycinfo or psyclit or healthstar or
biosis or current content*)).mp. [mp=abstract, heading words, title]
49. hta.mp. [mp=abstract, heading words, title]
50. (health technology adj6 assessment$).mp. [mp=abstract, heading words, title]
51. 45 or 46 or 47 or 48 or 49 or 50
52. 44 or 51
53. 34 and 52
HTA
1. exp diabetes mellitus type 2/
2. (MODY or NIDDM or T2DM or T2D).mp. [mp=title, text, subject heading word]
3. (non insulin$ depend$ or noninsulin$ depend$ or noninsulin?depend$ or non insulin?depend$).mp. [mp=title, text, subject
heading word]
4. ((typ? 2 or typ? II or typ?2 or typ?II) adj3 diabet$).mp. [mp=title, text, subject heading word]
5. (((late or adult$ or matur$ or slow or stabl$) adj3 onset) and diabet$).mp. [mp=title, text, subject heading word]
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6. 1 or 2 or 3 or 4 or 5
7. exp Mental disorders/
8. (mental adj6 (disorder* or illness)).mp. [mp=title, text, subject heading word]
9. (schizo* or psycho*).mp. [mp=title, text, subject heading word]
10. ((bipolar or affective or personality) adj6 disorder*).mp. [mp=title, text, subject heading word]
11. exp depression/
12. depression*.mp. [mp=title, text, subject heading word]
13. 7 or 8 or 9 or 10 or 11 or 12
14. 6 and 13
15. exp self care/
16. health education/
17. exp health promotion/
18. exp health behavior/
19. exp program evaluation/
20. exp life style/
21. (self adj6 (care or management or monitoring)).mp. [mp=title, text, subject heading word]
22. (patient adj6 (education* or compliance)).mp. [mp=title, text, subject heading word]
23. (health adj6 (promotion* or behavio?r*)).mp. [mp=title, text, subject heading word]
24. (program adj6 evaluation*).mp. [mp=title, text, subject heading word]
25. (behavio?ral adj6 (intervention* or therap* or treatment* or chang*)).mp. [mp=title, text, subject heading word]
26. ((psychosocial or psycho-social) adj6 (intervention* or treatment* or therap*)).mp. [mp=title, text, subject heading word]
27. (adherence or compliance).mp. [mp=title, text, subject heading word]
28. ((lifestyle or life style) adj6 (intervention* or chang*)).mp. [mp=title, text, subject heading word]
29. exp Weight loss/
30. (weight adj6 (management or los* or reduction*)).mp. [mp=title, text, subject heading word]
31. (lifestyle adj6 (intervention* or chang*)).mp. [mp=title, text, subject heading word]
32. exp comparative study/
33. exp random allocation/
34. exp Placebos/
35. exp prospective studies/
36. ((clinical or control$ or comparativ$ or placebo$ or prospectiv$ or randomi?ed) adj3 (trial$ or stud$)).mp. [mp=title, text, subject
heading word]
37. (random$ adj6 (allocat$ or assign$ or basis or order$)).mp. [mp=title, text, subject heading word]
38. ((singl$ or doubl$ or trebl$ or tripl$) adj6 (blind$ or mask$)).mp. [mp=title, text, subject heading word]
39. (cross over or crossover).mp. [mp=title, text, subject heading word]
40. exp Meta analysis/
41. (metaanaly$ or meta analy$ or meta?analy$).mp. [mp=title, text, subject heading word]
42. (review* adj6 systematic).mp. [mp=title, text, subject heading word]
43. (search* adj10 (medical databas*or medline or pubmed or embase or cochrane or cinahl or psycinfo or psyclit or healthstar or
biosis or current content*)).mp. [mp=title, text, subject heading word]
44. 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31
45. 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39
46. 40 or 41 or 42 or 43
47. 45 or 46
48. 14 and 44 and 47
NHS EDD
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1. exp diabetes mellitus type 2/
2. (MODY or NIDDM or T2DM or T2D).mp. [mp=title, text, subject heading word]
3. (non insulin$ depend$ or noninsulin$ depend$ or noninsulin?depend$ or non insulin?depend$).mp. [mp=title, text, subject
heading word]
4. ((typ? 2 or typ? II or typ?2 or typ?II) adj3 diabet$).mp. [mp=title, text, subject heading word]
5. (((late or adult$ or matur$ or slow or stabl$) adj3 onset) and diabet$).mp. [mp=title, text, subject heading word]
6. 1 or 2 or 3 or 4 or 5
7. exp Mental disorders/
8. (mental adj6 (disorder* or illness)).mp. [mp=title, text, subject heading word]
9. (schizo* or psycho*).mp. [mp=title, text, subject heading word]
10. ((bipolar or affective or personality) adj6 disorder*).mp. [mp=title, text, subject heading word]
11. exp depression/
12. depression*.mp. [mp=title, text, subject heading word]
13. 7 or 8 or 9 or 10 or 11 or 12
14. 6 and 13
15. exp patient education/
16. exp self care/
17. health education/
18. exp health promotion/
19. exp health behavior/
20. exp program evaluation/
21. exp life style/
22. (self adj6 (care or management or monitoring)).mp. [mp=title, text, subject heading word]
23. (patient adj6 (education* or compliance)).mp. [mp=title, text, subject heading word]
24. (health adj6 (promotion* or behavio?r*)).mp. [mp=title, text, subject heading word]
25. (program adj6 evaluation*).mp. [mp=title, text, subject heading word]
26. (behavio?ral adj6 (intervention* or therap* or treatment* or chang*)).mp. [mp=title, text, subject heading word]
27. ((psychosocial or psycho-social) adj6 (intervention* or treatment* or therap*)).mp. [mp=title, text, subject heading word]
28. (adherence or compliance).mp. [mp=title, text, subject heading word]
29. ((lifestyle or life style) adj6 (intervention* or chang*)).mp. [mp=title, text, subject heading word]
30. exp Weight loss/
31. (weight adj6 (management or los* or reduction*)).mp. [mp=title, text, subject heading word]
32. (lifestyle adj6 (intervention* or chang*)).mp. [mp=title, text, subject heading word]
33. 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32
34. 14 and 33
35. exp comparative study/
36. exp random allocation/
37. exp Placebos/
38. exp prospective studies/
39. ((clinical or control$ or comparativ$ or placebo$ or prospectiv$ or randomi?ed) adj3 (trial$ or stud$)).mp. [mp=title, text, subject
heading word]
40. (random$ adj6 (allocat$ or assign$ or basis or order$)).mp. [mp=title, text, subject heading word]
41. ((singl$ or doubl$ or trebl$ or tripl$) adj6 (blind$ or mask$)).mp. [mp=title, text, subject heading word]
42. (cross over or crossover).mp. [mp=title, text, subject heading word]
43. exp Meta analysis/
44. (metaanaly$ or meta analy$ or meta?analy$).mp. [mp=title, text, subject heading word]
45. (review* adj6 systematic).mp. [mp=title, text, subject heading word]
46. (search* adj10 (medical databas*or medline or pubmed or embase or cochrane or cinahl or psycinfo or psyclit or healthstar or
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biosis or current content*)).mp. [mp=title, text, subject heading word]
47. hta.mp. [mp=title, text, subject heading word]
48. (health technology adj6 assessment$).mp. [mp=title, text, subject heading word]
49. 43 or 44 or 45 or 46 or 47 or 48
50. 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42
51. 49 or 50
52. 34 and 51
CINAHL Plus
S1 (MH “Diabetes Mellitus, Type 2”)
S2 (MODY or NIDDM or T2DM or T2D)
S3 (non insulin* depend* or noninsulin* depend* or noninsulin?depend* or non insulin?depend*)
S4 ((typ* 2 or typ* II or typ#2 or typ#II) N3 diabet*)
S5 (((late or adult* or matur* or slow or stabl*) N3 onset) and diabet*)
S6 S1 or S2 or S3 or S4 or S5
S7 (MH “Mental Disorders, Chronic”) OR (MH “Mental Disorders+”) OR (MH “Psychotic Disorders+”) OR (MH “Personality
Disorders+”) OR (MH “Depression+”)
S8 (MH “Bipolar Disorder+”)
S9 (mental N6 (disorder* or disease* or illness))
S10 (schizo* or psycho*)
S11 ((bipolar or affective or personality) N6 (diseas* or disorder))
S12 depression*
S13 S7 or S8 or S9 or S10 or S11 or S12
S14 (MH “Patient Education”) OR (MH “Health Education”) OR (MH “Diabetes Education”)
S15 (MH “Self Care”) OR (MH “Self Administration”)
S16 (MH “Health Behavior+”)
S17 (MH “Program Evaluation”)
S18 (MH “Behavior Therapy”)
S19 (MH “Life Style”) OR (MH “Life Style, Sedentary”) OR (MH “Life Style Changes”)
S20 (MH “Health Promotion”)
S21 (self N6 (care or management or monitoring))
S22 (patient N6 (education* or compliance))
S23 (health N6 (promotion* or behavio#r*))
S24 (program N6 evaluation*)
S25 (behavio#ral N6 (intervention* or therap* or treatment* or chang*))
S26 ((psychosocial or psycho-social) N6 (intervention* or treatment* or therap*))
S27 (adherence or compliance)
S28 ((lifestyle or life style) N6 (intervention* or chang*))
S29 (MH “Weight Loss”)
S30 (MH “Weight Reduction Programs”)
S31 (weight N6 (management or los* or reduction*))
S32 (lifestyle N6 (intervention* or chang*))
S33 S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28 or S29 or S30 or S31
or S32
S34 (MH “Clinical Trials+”)
S35 (MH “Comparative Studies”)
S36 (MH “Random Assignment”)
S37 (MH “Prospective Studies”)
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S38 ((clinical or control* or comparativ* or placebo* or prospectiv* or randomi#ed) N3 (trial* or stud*))
S39 (random* N6 (allocat* or assign* or basis or order*))
S40 ((singl* or doubl* or trebl* or tripl*) N6 (blind* or mask*))
S41 (cross over or crossover)
S42 S34 or S35 or S36 or S37 or S38 or S39 or S40 or S41
S43 (MH “Meta Analysis”)
S44 (metaanaly* or meta analy* or meta#analy*)
S45 (review* N6 systematic)
S46 (search* N10 (medical database* or medline or pubmed or embase or cochrane or cinahl or psycinfo or psyclit or healthstar or
biosis or current content* or systematic*))
S47 (MH “Literature Review+”)
S48 hta
S49 (health technology N6 assessment*)
S50 S43 or S44 or S45 or S46 or S47 or S48 or S49
S51 S42 or S50
S52 S6 AND S13 AND S33 AND S51
C O N T R I B U T I O N S O F A U T H O R S
Hayley McBain (HM): protocol draft, search strategy development, acquiring trial reports, trial selection, data extraction, data analysis,
data interpretation, review draft and future review updates.
Kathleen Mulligan (KM): protocol draft, search strategy development, data extraction, data analysis, data interpretation, review draft
and future review updates.
Mark Haddad (MH): protocol draft, trial selection, data analysis, data interpretation, review draft and future review updates.
Chris Flood (CF): protocol draft, trial selection, data analysis, data interpretation, review draft and future review updates.
Julia Jones (JJ): protocol draft, data analysis, data interpretation, review draft and future review updates.
Alan Simpson (AS): protocol draft, data extraction, data analysis, data interpretation, review draft and future review updates
D E C L A R A T I O N S O F I N T E R E S T
HM: None known.
KM: None known.
MH: None known.
CF: None known.
JJ: None known.
AS: None known.
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N O T E S
The methods section and appendix 1 of this protocol are based on a standard template established by the Cochrane Metabolic and
Endocrine Disorders Group.
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